Bayer sells testosterone treatment to German company for $500M
Bayer AG is all set to sell its testosterone deficiency treatment Nebido to Grünenthal, a German pain management company for about $500 million.
The deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
